Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
Date:10/21/2011

the company and its product pipeline to investors on a conference call. To participate in the conference call, please call one of the following telephone numbers 15 minutes prior to the event, using access code 6749807: +31(0)20-721-9158 for the Netherlands and +44(0)20-3450-9987 for the UK. Following the presentation, the lines will be opened for questions. A replay of the call will be available following the event.

About Glybera®

AMT has developed Glybera as a treatment for patients with the genetic disorder lipoprotein lipase deficiency. LPLD is an orphan disease for which no treatment exists today. The disease is caused by mutations in the LPL gene, resulting in highly decreased or absent activity of LPL protein in patients. This protein is needed in order to break down large fat-carrying particles that circulate in the blood after each meal. When such particles, called chylomicrons, accumulate in the blood, they may obstruct small blood vessels. Excess chylomicrons result in recurrent and severe acute inflammation of the pancreas, called pancreatitis, the most debilitating and life-threatening clinical complication of LPLD. Glybera® has orphan drug status in the EU and US.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. In addition to Glybera, AMT has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  ArroGen Group, an integrated advanced ... Molecular Identification™ (FMID) technology Aug. 2-8 at the ... Sacramento, Calif. FMID, ... law enforcement agents, district attorneys and government agencies ... By analyzing chemical residues on fingerprints ...
(Date:8/3/2015)... , August 3, 2015 At ... Portland Hospital waved the shortfall of Jude ... stand normally for the first time.      ... http://photos.prnewswire.com/prnh/20150803/254229 ) The Selective Dorsal ... allowing him to carry out his wish to kick ...
(Date:8/3/2015)... , Aug. 3, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop and ... Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors ... the 35 th Annual Canaccord|Genuity Growth Conference in ... Petit, Chairman and CEO, William C. Taylor , ...
(Date:8/3/2015)... ... August 03, 2015 , ... The ... processed to get such derivatives as ethylbenzene, a precursor to styrene, used to ... the automotive industry for the production of tyres and other components. Thus, growth ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3
... 27, 2010 , , , ... - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its,Clinical Safety* and Efficacy ... Cordis Corporation, a worldwide ... Vascular Closure Device. ExoSeal(TM) incorporates a number of new,advances in technology and simplicity of ...
... ,,, ... 26, 2010, QIAGEN N.V. (NASDAQ: ... Prime Standard: QIA [, http://www.boerse-frankfurt.de/DE/index.aspx?pageID=35&ISIN=NL0000240000 ... an agreement with Roche Molecular Systems,Inc., ...
... increase crop yields and productivity, create sustainable forests and new medicines, and ... in the world,s poorest countries, will be among the recurring themes of ... Congress, June 6-11, 2010 , at the America,s Center ... , , ...
Cached Biology Technology:CORDIS Launches ExoSeal(TM) Vascular Closure Device 2CORDIS Launches ExoSeal(TM) Vascular Closure Device 3CORDIS Launches ExoSeal(TM) Vascular Closure Device 4QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 2QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 3QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 4QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 5QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 6Plant BioTech World Congress to Highlight Scientific Discoveries and Technologies Bringing New Hope to Feeding the World and Improving Lives 2Plant BioTech World Congress to Highlight Scientific Discoveries and Technologies Bringing New Hope to Feeding the World and Improving Lives 3
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... uncovered an important step in how herpes simplex virus, ... to gain entry into healthy cells and infect them. ... the effectiveness of monitoring these protein interactions using biomolecular ... the National Academy of Sciences, provide a better understanding ...
... Access publisher for Physics, Mathematics and Computer Science, ... DESY high-energy physics laboratories. Under these agreements ... all research published by their investigators in the ... PMC Physics A is edited by professor Ken ...
... connect silicon circuits with brains are under intensive ... commercial application in many areas, according to a ... Berger of the University of Southern California chaired ... of Research and Development in Brain-Computer Interfaces," published ...
Cached Biology News:Penn researchers shine the light of venus to learn how the herpes virus invades cells 2Top physics laboratories sign up to open access with PhysMath Central 2Brain-computer link systems on the brink of breakthrough, study finds 2
... of the human Topoisomerase II gene. ... state of nucleic acids by passing an intact ... a separate DNA helix (1,2) . As a ... enzyme can relax negatively or positively supercoiled DNA, ...
... the template-directed polymerization of nucleotides into duplex ... I possesses a 3?5 exonuclease activity or ... during DNA replication, and also contains a ... to replace nucleotides in the growing strand ...
... is a genetically engineered Klenow polymerase in which ... removed, leaving only the 5 to 3 polymerase ... Klenow Fragment the enzyme of choice for isotopic ... random primed method, and for DNA sequencing by ...
Request Info...
Biology Products: